Aarti Drugs Ltd's Q4FY25 Quarter Results
- 07 May 2025
Result Summary
- Aarti Drugs Ltd reported a 9.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 16.4%.
- Its expenses for the quarter were up by 7.6% QoQ and down 16.9% YoY.
- The net profit increased 27.6% QoQ and decreased 15.8% YoY.
- The earnings per share (EPS) of Aarti Drugs Ltd stood at 5.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 621.07 | 568.50 | 743.28 | 9.2% | -16.4% |
Total Expenses | 556.89 | 517.74 | 670.00 | 7.6% | -16.9% |
Profit Before Tax | 64.18 | 50.76 | 73.28 | 26.4% | -12.4% |
Tax | 16.87 | 13.67 | 17.10 | 23.4% | -1.3% |
Profit After Tax | 47.31 | 37.09 | 56.18 | 27.6% | -15.8% |
Earnings Per Share | 5.20 | 4.10 | 6.10 | 26.8% | -14.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aarti Drugs Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company caters to a wide range of therapeutic segments, including antibiotics, anti-inflammatory, anti-diabetic, and cardiovascular medications, among others. Aarti Drugs has established a robust presence in both domestic and international markets, leveraging its extensive manufacturing capabilities and a broad product portfolio. While there are no specific recent developments provided in the data, the company is known for its continuous focus on enhancing its product offerings and expanding its market reach.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Aarti Drugs Ltd reported a total income of ₹621.07 crores. This represented a quarter-over-quarter (QoQ) increase of 9.2% from the previous quarter (Q3FY25), where the total income was ₹568.50 crores. However, when compared to the same quarter of the previous fiscal year (Q4FY24), the total income saw a year-over-year (YoY) decline of 16.4% from ₹743.28 crores. This indicates a fluctuation in revenue performance over the year, with a notable decline in comparison to the previous year's corresponding quarter.
Profitability
The company reported a profit before tax (PBT) of ₹64.18 crores in Q4FY25, a 26.4% increase from the ₹50.76 crores recorded in Q3FY25. However, this figure represents a 12.4% decrease compared to the ₹73.28 crores reported in Q4FY24. The profit after tax (PAT) for Q4FY25 was ₹47.31 crores, marking a QoQ growth of 27.6% from Q3FY25's ₹37.09 crores, but a YoY decrease of 15.8% from ₹56.18 crores in Q4FY24. Tax expenses for the quarter were ₹16.87 crores, reflecting a 23.4% QoQ increase and a slight 1.3% YoY decrease. Earnings per share (EPS) in Q4FY25 stood at ₹5.20, up 26.8% from Q3FY25's ₹4.10, yet down 14.8% from ₹6.10 in Q4FY24.
Operating Metrics
The total expenses for Aarti Drugs Ltd in Q4FY25 were reported at ₹556.89 crores, which signifies a QoQ increase of 7.6% from the ₹517.74 crores in Q3FY25. This also represents a YoY decrease of 16.9% from the ₹670.00 crores recorded in Q4FY24. The company's operating performance, as reflected in these expenses, shows a reduction in costs compared to the same period last year, despite a rise from the previous quarter. No specific operational metrics such as production volume or sales growth metrics are available from the provided data.
